Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Aardvark Therapeutics Inc. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners. The portfolio is active across 2 distinct art units, indicating that the company's pharmaceutical research is being reviewed in 2 different technical classifications at the USPTO. This distribution across 2 distinct art units suggests that the company's filings are concentrated enough to fall into a limited number of technical classifications.
SAHIL CHANDER AGGARWAL is the busiest examiner for the company, overseeing 1 busiest examiner pending office action. With 3 pending office actions and 3 distinct examiners, the workload is split such that each examiner handles 1 case. This distribution across 2 distinct art units and 3 examiners suggests a manageable prosecution landscape for the company's current filings. Practitioners must maintain 3 separate examiner relationships while navigating the 2 distinct art units involved in the current docket. This structure allows for diverse examiner perspectives while keeping the technical focus within specific areas.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| HIBBERT, CATHERINE S | 1 | 58.9% | +48.8% |
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | AGGARWAL, SAHIL CHANDER | — |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | IVANOVA, SVETLANA M | 60d overdue |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18924880 | Abuse-Deterrent Pharmaceutical Composition with Aversion Properties | AGGARWAL, SAHIL CHANDER | — | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18557182 | COMBINATION OF BITTER RECEPTOR AGONIST AND GUT-SIGNALING COMPOUND | HIBBERT, CATHERINE S | 1658 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17845399 | Pharmaceutical Composition for Treatment or Prevention of Multiple Inflammatory disorders | IVANOVA, SVETLANA M | 1627 | §103 | Non-Final OA | 60d overdue | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial